Redmile Group LLC increased its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report) by 944.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,164,126 shares of the company’s stock after purchasing an additional 1,956,923 shares during the period. Redmile Group LLC’s holdings in Ventyx Biosciences were worth $11,903,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in VTYX. Tower Research Capital LLC TRC grew its position in Ventyx Biosciences by 1,424.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock worth $49,000 after purchasing an additional 18,620 shares in the last quarter. Federated Hermes Inc. bought a new stake in Ventyx Biosciences in the fourth quarter worth about $50,000. Norden Group LLC bought a new position in Ventyx Biosciences during the first quarter valued at $59,000. China Universal Asset Management Co. Ltd. increased its holdings in Ventyx Biosciences by 66.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock worth $63,000 after acquiring an additional 4,553 shares during the last quarter. Finally, Aigen Investment Management LP bought a new stake in shares of Ventyx Biosciences in the fourth quarter valued at approximately $65,000. 97.88% of the stock is owned by institutional investors.
Analyst Ratings Changes
VTYX has been the topic of a number of recent research reports. HC Wainwright reissued a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Thursday, June 13th. Oppenheimer lowered their price target on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, June 6th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.75.
Ventyx Biosciences Trading Down 22.7 %
VTYX stock traded down $0.67 during midday trading on Monday, hitting $2.28. The company had a trading volume of 4,121,144 shares, compared to its average volume of 2,524,112. The stock has a market cap of $160.74 million, a price-to-earnings ratio of -0.70 and a beta of 0.40. Ventyx Biosciences, Inc. has a 52 week low of $1.87 and a 52 week high of $38.20. The stock’s 50 day moving average price is $3.17 and its 200 day moving average price is $4.17.
Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. During the same quarter in the previous year, the company earned ($0.68) earnings per share. Analysts predict that Ventyx Biosciences, Inc. will post -2.31 earnings per share for the current year.
Ventyx Biosciences Profile
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
See Also
- Five stocks we like better than Ventyx Biosciences
- What is Short Interest? How to Use It
- Survey: Top 175 Fittest Retirement Locations in America
- What Are Dividend Achievers? An Introduction
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Want to see what other hedge funds are holding VTYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. (NASDAQ:VTYX – Free Report).
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.